×







We sell 100% Genuine & New Books only!

Novel Inhibitors of Leukotrienes 1st Editon 2012 Softbound at Meripustak

Novel Inhibitors of Leukotrienes 1st Editon 2012 Softbound by Giancarlo Folco, Bengt Samuelsson, Robert C. Murphy, Birkhäuser

Books from same Author: Giancarlo Folco, Bengt Samuelsson, Robert C. Murphy

Books from same Publisher: Birkhäuser

Related Category: Author List / Publisher List


  • Price: ₹ 15533.00/- [ 15.00% off ]

    Seller Price: ₹ 13203.00

Estimated Delivery Time : 4-5 Business Days

Sold By: Meripustak      Click for Bulk Order

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

We deliver across all postal codes in India

Orders Outside India


Add To Cart


Outside India Order Estimated Delivery Time
7-10 Business Days


  • We Deliver Across 100+ Countries

  • MeriPustak’s Books are 100% New & Original
  • General Information  
    Author(s)Giancarlo Folco, Bengt Samuelsson, Robert C. Murphy
    PublisherBirkhäuser
    Edition1st Edition
    ISBN9783034897365
    Pages347
    BindingSoftbound
    LanguageEnglish
    Publish YearOctober 2012

    Description

    Birkhäuser Novel Inhibitors of Leukotrienes 1st Editon 2012 Softbound by Giancarlo Folco, Bengt Samuelsson, Robert C. Murphy

    Many new antileukotriene drugs are now marketed as antiasthma drugs and represent the first new drugs in this field since the 1970s. This book covers the steps that have led to the discovery and development of these new drugs and offers detailed descriptions of their clinical applications. The review chapters on the main aspects of basic and applied leukotriene research are written by leading specialists in the field, and the volume takes a new approach in presenting information of particular interest to both scientists and clinicians in the fields of asthma, inflammation and allergic diseases. 5-Lipoxygenase.- LTC4 synthase: A key enzyme in cysteinyl leukotriene formation.- Leukotriene A4 hydrolase: A key enzyme in chemotactic leukotriene formation.- Metabolism of leukotrienes and formation of new leukotriene structures.- Receptors for cysteinyl-leukotrienes: Targets for new drugs.- Targeted disruption of 5-lipoxygenase.- Transcellular biosynthesis of leukotrienes: A unique mode of cell communication.- Physiological and pathophysiological activities of leukotrienes.- Entry rate and metabolic handling of LTC4 in the human circulation.- Genetic polymorphisms of 5-LO.- Leukotrienes and aspirin-intolerant asthma.- Leukotrienes in nocturnal asthma.- Leukotrienes and allergic asthma.- Inhibitors of leukotrienes: An overview.- The development of zafirlukast (Accolate®) and the Zeneca series of peptidyl-leukotriene receptor antagonists.- The development of zileuton (ZYFLO®) and the N-hydroxyurea class of 5-lipoxygenase inhibitors.- The development of BAY X 1005 and the Bayer series of leukotriene biosynthesis inhibitors.- The development of iralukast: A member of the Novartis series of cysteinyl leukotriene antagonists.- LTB4 receptor antagonists.- SmithKline Beecham pharmaceuticals’ cysteinyl leukotriene receptor antagonists: Pranlukast (SB 205312; Ono-1078; Onon), Pobilukast (SK&F 104353) and SK&F 106203.



    Book Successfully Added To Your Cart